AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Genes & Diseases Article
PDF (293.1 KB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Review Article | Open Access

Highlights of the 2015 San Antonio Breast Cancer Symposium

Mark Keatona, Debu Tripathyb, Joyce O'Shaughnessyc, Shou-Ching Tanga,d,( )
Georgia Regents University Cancer Center, 1411 Laney Walker Blvd., Augusta, GA 30912, USA
The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Unit 1354, Houston, TX 77030, USA
Baylor University Medical Center, Texas Oncology, US Oncology, 3410 Worth St Suite 400, Dallas, TX 75246, USA
Tianjin Medical University Cancer Institute and Hospital, Tianjin, China

Peer review under responsibility of Chongqing Medical University.

Show Author Information

Abstract

This manuscript provides a comprehensive review and highlights of the 2015 San Antonio Breast Cancer Symposium by the leading breast cancer specialists and investigators in the field.

Keywords

BiomarkersDiagnosis and treatmentSan Antonio Breast Cancer highlightsBreast cancer prognosisImmunotherapy and targeted therapies

References

1

Jiang D, Gao Z, Cai Z, Wang M, He J. Clinicopathological and prognostic significance of FOXP3+ tumor infiltrating lymphocytes in patients with breast cancer: a meta-analysis. BMC Cancer. 2015;15:727.
Crossref Google Scholar
2

Dushyanthen S, Beavis PA, Savas P, et al. Relevance of tumor-infiltrating lymphocytes in breast cancer. BMC Med. 2015;13:202.
Crossref Google Scholar
3

Salgado R, Denkert C, Demaria S, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an international TILs working group 2014. Ann Oncol. 2015;26:259-271.
Crossref Google Scholar
4

Pruneri G, Vingiani A, Bagnardi V, et al. Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple negative breast cancer. Ann Oncol. 2016;27:249-256.
Crossref Google Scholar
5

Jeselsohn R, Yelensky R, Buchwalter G, et al. Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer. Clin Cancer Res. 2014 Apr 1;20:1757-1767.
Crossref Google Scholar
6

Segal CV, Dowsett M. Estrogen receptor mutations in breast cancer – new focus on an old target. Clin Cancer Res. April 2014;20:1724-1726.
Crossref Google Scholar
7

Guttery DS, Page K, Hills A, et al. Noninvasive detection of activating estrogen receptor 1 (ESR1) mutations in estrogen receptor-positive metastatic breast cancer. Clin Chem. 2015;61:974-982.
Crossref Google Scholar
8

Brigitte R, Christian S, Julia J, et al, on behalf of the SUCCESS Study Group. Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. JNCI J Natl Cancer Inst. 2014;106(5).
Crossref Google Scholar
9

Sparano JA, Gray RJ, Makower DF, et al. Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med. 2005-2014;373(21).
Crossref Google Scholar
10

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Coleman R, Powles T, Paterson A, et al. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet. 2015;386:1353-1361.
Crossref Google Scholar
11

O'Shaughnessy J, Koeppen H, Xiao Y, et al. Patients with slowly proliferative early breast cancer have low five-year recurrence rates in phase Ⅲ adjuvant trial of capecitabine. Clin Cancer Res. 2015; Oct 1;21:4305-4311.
Crossref Google Scholar
12

Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, et al. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial. J Clin Oncol. 2012 Jan 1;30:11-18.
Crossref Google Scholar
Genes & Diseases
Volume 3 Issue 2,
June 2016
Pages 110-113
DOI: 10.1016/j.gendis.2016.03.002
Cite this article:
Keaton M, Tripathy D, O'Shaughnessy J, et al. Highlights of the 2015 San Antonio Breast Cancer Symposium. Genes & Diseases, 2016, 3(2): 110-113. https://doi.org/10.1016/j.gendis.2016.03.002

225

Views

1

Downloads

0

Crossref

N/A

Web of Science

0

Scopus

0

CSCD

Altmetrics
Received: 07 March 2016
Accepted: 14 March 2016
Published: 25 March 2016
© 2016, Chongqing Medical University.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Return